ReviewMetabolites2020
Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer.
Review in Metabolites, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- A Comprehensive Review on Strategies of Topical Niosomes and Their Synergistic Effect for Enhanced Therapeutic Outcomes.Pharmaceutical nanotechnology · 2026Review
- Detecting metabolic signatures in endometrial cancer: potential applications of Raman spectroscopy.Future oncology (London, England) · 2025Review
- EphA5 Expression Predicts Better Survival Despite an Association with Proliferative Activity in Endometrial Cancer.Journal of clinical medicine · 2025Article
- Metabolomics in cancer detection: A review of techniques, biomarkers, and clinical utility.BioMedicine · 2025Review
- Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment.Cancers · 2024Review
- Cervical mucus can be used for metabolite screening in cervical cancer.Cancer science · 2024Article
- Multi-omic analyses identified SFRP4 as a novel biomarker in abnormal uterine bleeding with ovulatory dysfunction.Heliyon · 2024Article
- Revolutionizing Gastrointestinal Disorder Management: Cutting-Edge Advances and Future Prospects.Journal of clinical medicine · 2024Review
- Plasma-based proteomic profiling identifies the distinct regulation of proteins in hyperplasia and endometrial cancer.BMC cancer · 2024Article
- Palmitic Acid Exerts Anti-Tumorigenic Activities by Modulating Cellular Stress and Lipid Droplet Formation in Endometrial Cancer.Biomolecules · 2024Article
- Endogenous estrogen metabolites as oxidative stress mediators and endometrial cancer biomarkers.Cell communication and signaling : CCS · 2024Review
- Metabolomic Profiling of Blood Plasma in Females with Hyperplasia and Endometrial Cancer.Metabolites · 2024Article
- The effect of lipidomes on the risk of endometrioid endometrial cancer: a Mendelian randomization study.Frontiers in oncology · 2024Article
- Metabolomic-Based Approaches for Endometrial Cancer Diagnosis and Prognosis: A Review.Cancers · 2023Review
- Identification of Potentially Novel Molecular Targets of Endometrial Cancer Using a Non-Biased Proteomic Approach.Cancers · 2023Article
- Quantitative SWATH-based proteomic profiling of urine for the identification of endometrial cancer biomarkers in symptomatic women.British journal of cancer · 2023Article
- Endometrial cancer diagnostic and prognostic algorithms based on proteomics, metabolomics, and clinical data: a systematic review.Frontiers in oncology · 2023Review
- Altered Gut Microbial Profile Accompanied by Abnormal Fatty Acid Metabolism Activity Exacerbates Endometrial Cancer Progression.Microbiology spectrum · 2022Article
- The Metabolomic Approach for the Screening of Endometrial Cancer: Validation from a Large Cohort of Women Scheduled for Gynecological Surgery.Biomolecules · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Metabolic reprogramming is increasingly recognised as one of the defining hallmarks of tumorigenesis. There is compelling evidence to suggest that endometrial cancer develops and progresses in the context of profound metabolic dysfunction. Whilst the incidence of endometrial cancer continues to rise in parallel with the global epidemic of obesity, there are, as yet, no validated biomarkers that can aid risk prediction, early detection, prognostic evaluation or surveillance. Advances in high-throughput technologies have, in recent times, shown promise for biomarker discovery based on genomic, transcriptomic, proteomic and metabolomic platforms. Metabolomics, the large-scale study of metabolites, deals with the downstream products of the other omics technologies and thus best reflects the human phenotype. This review aims to provide a summary and critical synthesis of the existing literature with the ultimate goal of identifying the most promising metabolite biomarkers that can augment current endometrial cancer diagnostic, prognostic and recurrence surveillance strategies. Identified metabolites and their biochemical pathways are discussed in the context of what we know about endometrial carcinogenesis and their potential clinical utility is evaluated. Finally, we underscore the challenges inherent in metabolomic biomarker discovery and validation and provide fresh perspectives and directions for future endometrial cancer biomarker research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.